Dyne Therapeutics (DYN) Stock Forecast & Price Target

$33.83

-0.79 (-2.28%)

(As of 09/27/2024 ET)

Dyne Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 10 Analyst Ratings

Sell
0

Hold
0

Buy
10

Based on 10 Wall Street analysts who have issued ratings for Dyne Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 9 have given a buy rating, and 1 has given a strong buy rating for DYN.

Consensus Price Target

$51.40
51.94% Upside

According to the 10 analysts' twelve-month price targets for Dyne Therapeutics, the average price target is $51.40. The highest price target for DYN is $66.00, while the lowest price target for DYN is $42.00. The average price target represents a forecasted upside of 51.94% from the current price of $33.83.

Get the Latest News and Ratings for DYN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors.

DYN Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$51.40	$50.60	$40.78	$27.20
Forecasted Upside	51.94% Upside	11.80% Upside	15.55% Upside	203.57% Upside
Consensus Rating	Buy	Buy	Buy	Buy

WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)

The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.

Take these 4 steps today to protect your retirement NOW

DYN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DYN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Dyne Therapeutics Stock vs. The Competition

Type	Dyne Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.10	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	51.94% Upside	818.62% Upside	6.14% Upside
News Sentiment Rating	Neutral News See Recent DYN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/23/2024	Piper Sandler 2 of 5 stars	Reiterated Rating	Overweight ➝ Overweight	$53.00 ➝ $53.00	+44.85%
9/4/2024	HC Wainwright 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00	+72.20%
9/3/2024	Oppenheimer 3 of 5 stars	Reiterated Rating	Outperform ➝ Outperform	$55.00 ➝ $55.00	+78.80%
8/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$41.00 ➝ $66.00	+44.29%
8/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$45.00 ➝ $50.00	+8.98%
8/14/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$48.00 ➝ $52.00	+19.16%
Get the Latest News and Ratings for DYN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
7/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$39.00 ➝ $43.00	+25.58%
5/21/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$31.00 ➝ $42.00	+18.71%
5/20/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$36.00 ➝ $42.00	+22.77%
1/4/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Strong-Buy ➝ Strong-Buy	$27.00 ➝ $56.00	+279.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:26 AM ET.

DYN Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Dyne Therapeutics is $51.40, with a high forecast of $66.00 and a low forecast of $42.00.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
: According to analysts, Dyne Therapeutics's stock has a predicted upside of 51.94% based on their 12-month stock forecasts.
: Dyne Therapeutics has been rated by research analysts at Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, and Stifel Nicolaus in the past 90 days.
: Analysts like Dyne Therapeutics more than other "medical" companies. The consensus rating for Dyne Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DYN compares to other companies.